Cargando…
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
Patients with non-Hodgkin lymphoma (NHL) are treated today with a cocktail of drugs referred to as CHOP (Cyclophosphamide, Hydroxyldaunorubicin, Oncovin, and Prednisone). Subsets of patients with NHL of germinal center origin bear oncogenic mutations in the EZH2 histone methyltransferase. Clinical t...
Autores principales: | Knutson, Sarah K., Warholic, Natalie M., Johnston, L. Danielle, Klaus, Christine R., Wigle, Tim J., Iwanowicz, Dorothy, Littlefield, Bruce A., Porter-Scott, Margaret, Smith, Jesse J., Moyer, Mikel P., Copeland, Robert A., Pollock, Roy M., Kuntz, Kevin W., Raimondi, Alejandra, Keilhack, Heike |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262195/ https://www.ncbi.nlm.nih.gov/pubmed/25493630 http://dx.doi.org/10.1371/journal.pone.0111840 |
Ejemplares similares
-
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor
with Robust in Vivo Activity
por: Campbell, John E., et al.
Publicado: (2015) -
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
por: Kawano, Satoshi, et al.
Publicado: (2016) -
Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
por: Kawano, Satoshi, et al.
Publicado: (2017) -
Loss of BAP1 function leads to EZH2-dependent transformation
por: LaFave, Lindsay M., et al.
Publicado: (2015) -
A Medium-Throughput Single Cell CRISPR-Cas9 Assay to Assess Gene Essentiality
por: Grassian, A. R., et al.
Publicado: (2015)